Health ASCO 2023: IDH mutation and improved cognitive functions in brain tumor patients by Alexandra Hartman Editor-in-Chief June 4, 2023 written by Alexandra Hartman Editor-in-Chief June 4, 2023 45 2023-06-04 12:19:42 – ASCO 2023 ASCO 2023 Patients with this tumor with the IDH 1 and 2 mutation improve their motor and cognitive functions, in addition to avoiding long-term relapses. Grade 2 gliomas with a mutation in the IDH gene are malignant brain tumors that cause considerable morbidity and premature death. 1685882522 #Vorasidenib #stops #grade #glioma #surgery #delays #chemo #radium Share this: Share on Facebook (Opens in new window) Facebook Share on X (Opens in new window) X 0 comments 0 FacebookTwitterPinterestEmail Alexandra Hartman Editor-in-Chief Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity. previous post Despite Dementia, Bruce Willis Enjoys a Day at Disneyland with Wife and Children next post Amazon is negotiating with US carriers to provide low-cost mobile phone service You may also like Here are several title options, ranging in tone... February 13, 2026 Here are several title options, ranging from concise... February 13, 2026 Fish Oil’s Cancer-Fighting Potential Hinges on a Key... February 13, 2026 Living Well with Obstructive HCM: Tips for Daily... February 13, 2026 AI-Powered Stethoscopes Improve Detection of Heart Valve Disease February 13, 2026 Healthcare Innovation Roundup: February 12, 2026 February 13, 2026 Here are a few title options, ranging from... February 13, 2026 Expanding Access to Assistance Dogs: Innovative Approaches February 13, 2026 Verbal Consent for Medical Student Involvement in Clinical... February 13, 2026 Low‑Fat Vegan Diet Cuts Type 1 Diabetes Insulin Use... February 13, 2026 Leave a Comment Cancel Reply Δ This site uses Akismet to reduce spam. Learn how your comment data is processed.
